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CaM pharmacologyThe prominent role of Ca2+ in cell physiology is mediated by a whole set of proteins involved in Ca2+-signal
generation, deciphering and arrest. Among these intracellular proteins, calmodulin (CaM) known as a proto-
typical calcium sensor, serves as a ubiquitous carrier of the intracellular calcium signal in all eukaryotic cell
types. CaM is assumed to be involved in many diseases including Parkinson, Alzheimer, and rheumatoid
arthritis. Defects in some of many reaction partners of CaMmight be responsible for disease symptoms. Several
classes of drugs bind to CaM with unwanted side effects rather than speciﬁc therapeutic use. Thus, it may be
more promising to concentrate at searching for pharmacological interferences with the CaM target proteins, in
order to ﬁnd tools for dissecting and investigating CaM-regulatory and modulatory functions in cells.
In the present study, we have established a screening assay based on ﬂuorescence polarization (FP) to identify a
diverse set of smallmolecules that disrupt the regulatory function of CaM. The FP-based CaMassay consists in the
competition of two ﬂuorescent probes and a library of chemical compounds for binding to CaM.
Screening of about 5300 compounds (Strasbourg Academic Library) by displacement of the probe yielded 39
compounds in a ﬁrst step, from which 6 were selected. Those 6 compounds were characterized by means of
calorimetry studies and by competitive displacement of two ﬂuorescent probes interacting with CaM. More-
over, those small molecules were tested for their capability to displace 8 different CaM binding domains from
CaM. Our results show that these CaM/small molecules interactions are not functionally equivalent.
The strategy that has been set up for CaM is a general model for the development and validation of other CaM
interactors, to decipher their mode of action, or rationally design more speciﬁc CaM antagonists. Moreover,
this strategy may be used for other protein binding assays intended to screen for molecules with preferred
binding activity. This article is part of a Special Issue entitled: 12th European Symposium on Calcium.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Ca2+ acts as a global second messenger in cell physiology and its
role is mediated by a whole set of proteins involved in Ca2+-signal
generation, deciphering and arrest. Among these intracellular proteins,
calmodulin (CaM), a fundamental calcium-modulated protein, has been
selected along evolution as a calcium hub in eukaryotes. It exerts a
major role in regulating both calcium homeostasis and intracellular
signaling. CaM is assumed to be involved in many diseases includingopean Symposium on Calcium.
33 368854310.
.
pidémiologie de l'Insufﬁsance
Médecine, Site Bichat, 16, Rue
l rights reserved.Parkinson, Alzheimer, and rheumatoid arthritis [1–3]. CaM interacting
small molecules have been sought and largely used in biological labora-
tories,mainly in the 80s. However, a substantial number of them tend to
do so with low speciﬁcity and uncertain stoichiometry [4]. Several
classes of hydrophobic small molecules including phenothiazines,
naphthalene sulphonamides, imidazoles and dihydropyridines bind to
CaM with afﬁnities in the micromolar range and inhibit its ability to
activate target enzymes. Thus, to ﬁnd tools allowing dissection and
investigation of CaM-dependent pathways, it may be more promising
to concentrate the search on pharmacological interference between
CaM and its target proteins [5]. The co-crystallization of CaM with
various small antagonists illustrates the plasticity of CaM, with its
ability to adapt its shape to different molecules [6–8].
Recently, the use of CaM antagonists resumed due to the renewal of
chemical biology. Moreover, CaM could be an interesting therapeutic
target in some types of cancers and inﬂammatory diseases [9–11].
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Ca2+/CaM complex inhibit the growth of a variety of tumor cells
[9,12,13].
In a previous study, a ﬂuorescence polarization (FP) based screen of
a chemical library allowed us to disclose a set of diverse compounds
that can be used as tools to decipher the role of CaM in regulating intra-
cellular calcium signaling [14]. In this paper, we ﬁrst describe the appli-
cation of this competitive FP-based assay that uses the ﬂuorescent
probes 16B05 (probe S1) or 17F07 (probe S3) characterized previously
[14] to the screening of CaMwith the collection of chemical compounds
of the Strasbourg Academic Library. The CaMbinding characteristics of a
subset of the compounds disclosed were further studied using biophys-
ical approaches. Finally, we analyze the ability of such compounds to
inhibit the interaction between CaM and several CaM-binding domains
using an assay described previously [15]. Comparing the behavior of the
CaM antagonists reveals that the small molecules are not functionally
equivalent. These ﬁndings indicate that analyzing data obtained by
using CaM antagonists to evaluate the role of CaM in a cellular event
must be donewith caution. On the other hand, those results rejuvenate
the pharmacology of CaM.
2. Experimental section
2.1. Materials
All chemicals were obtained from commercial suppliers and used
without further puriﬁcation. DMSO, KCl, and Hepes were purchased
from Sigma. CaCl2 was from Fluka. Ultra-purewater (Milli Q instrument
fromMillipore Corp., MA, USA) was used for the aqueous solutions. The
assays were carried out with synthetic CaM (SynCaM), a hybrid be-
tweenmammalian and plant CaM [16] orwith human CaM. Fluorescent
probes CHPO 199-5-B05 and CHPO 199-6-F07 ortho isomers (16B05
ortho and 17F07 ortho, respectively)were selected from the ﬂuorescent
polarization screening assay applied to CaM and characterized
biophysically [14]. Peptides were synthesized by Jena as previously
described [15]. Their purity is higher than 85%. 10 mM stock solutions
of peptides in DMSO were prepared.
2.2. Strasbourg Academic Library
The screened chemical library belongs to the Platform of Integrative
Chemical Biology of Strasbourg (PCBIS) and is a member of the core
facilities of the CNRS called “National Chemical Library” (http://
chimiotheque-nationale.enscm.fr/) which collects and itemizes all
molecules available from the participating laboratories in France. The
chemical library includes more than 5300molecules itemized and clas-
siﬁed in the database (MDL® ISIS/Base and Activity Base) and condi-
tioned in master microtube plates applying industrial standards. They
are stored in 96wellmicroplates under normalized conditions, at a con-
centration of about 10 mM in DMSO for automated screening assays.
The selected chemical compounds are royalty-free and their methods
of synthesis are known. The purity of the components is more than
80% (characterized by LC–MS). Addition of natural products and
extracts increases the diversity of the library. The Strasbourg Academic
Library is the initiator of the French National Chemical Library. Since
January 16th 2007, the chemical library platform has obtained the cer-
tiﬁcate of approval ISO 9001:2000.
The molecules identiﬁed in this study and their physical and chem-
ical characteristics are available upon request from Pascal Villa and
Bruno Didier for non-commercial purpose. All the molecules have
been characterized by LC–MS and their purity is greater than 95%.
2.3. Spectroscopic measurements
Steady-state absorption spectra were recorded on a NanoDrop
ND-1000 apparatus (Labtech) spectrophotometer in order to determinethe protein concentrations. Extinction coefﬁcients of 1650 M−1 cm−1
were used for SynCaM (VU1) [15]. All spectra were corrected for lamp
intensity variations and background. All the measurements were car-
ried out at 20 °C.
2.4. CaM screening assay based on ﬂuorescence polarization (FP)
Competitive FP-screening assays were performed with each of the
two probes (16B05 ortho isomer and 17F07 ortho isomer) using a
Victor3 apparatus (Perkin-Elmer Life and Analytical Sciences, Boston,
MA), handled by a Biomek 2000 robot, conducted in Corning Costar
96-well black polystyrene ﬂat-bottomed plates (Model 3686; Corning,
Acton, MA) and carried out at 25 °C. The Strasbourg Academic Library
was screened by adding to each well, successively, 15 μL of a library
compound at 20 μM in the assay buffer (50 mM Hepes, 150 mM KCl,
10 μM CaCl2 pH 7.5) and 15 μL of the mixture composed of 4 μM of
CaM and 0.2 μM of the ﬂuorescent probe prepared in the same buffer.
Control wells were planned for each plate, by means of 6 wells
containing the ﬂuorescent probe (0.1 μM) bound to CaM (2 μM) in a
ﬁnal volume of 30 μL and 6 wells containing 0.1 μM of probe alone
(unbound probe) in 30 μL of the solution buffer. The plate was stirred
and incubated for 5 min at room temperature. The equilibriumbetween
a ﬁxed concentration of the ﬂuorescent probe and its increasing free
concentration, as a result of the probe displacement by library com-
pounds, was monitored by ﬂuorescence polarization (FP). The polariza-
tion degrees were measured with an excitation wavelength set at
530 nm (bandwidth 7 nm) and an emission wavelength set at 610 nm
(bandwidth 10 nm). The ﬂuorescent probes used (16B05 (probe S1)
or 17F07 (probe S3)) consist of two pharmacophores fused to the ﬂuo-
rescent molecule lissamine [14].
2.5. Data analysis
The polarization degree is deﬁned by the equation P=(I//− I⊥)/
(I//+I⊥) where P is the ﬂuorescence polarization degree, I// and I⊥
are the ﬂuorescence intensities of the light emitted, respectively,
parallel (//) and perpendicular (⊥) with respect to the plane of linearly
polarized excitation light. For each plate, background correction was
done by subtracting blank parallel and perpendicular components (the
means of 2 wells containing only buffer) from the respective intensities.
When calculation are performed on FP data, anisotropy rather then po-
larization degree values are used, because they can be combined addi-
tively [17]. Anisotropy values (A) were obtained from polarization (P)
as follows [17]:
A ¼ 2Ρ
3−Ρ :
2.6. Calculation of the Z′-factor
To assess the suitability of the assay for high-throughput screening
applications, the Z′ value was calculated using the equation: Z′=1−
(3SDbound+3SDfree)/(mPbound−mPfree), where SD is the standard de-
viation and mP is the ﬂuorescence polarization expressed as P×1000,
where P stands for the polarization degree. The “bound state” is repre-
sented by the ﬂuorescent probe bound to the protein and the “free
state” is represented by the unbound ﬂuorescent probe prepared in
the solution buffer.
2.7. Biophysical characterization of CaM selected interactors
FP-titrations were performed using a Victor3 apparatus (Perkin-
Elmer Life and Analytical Sciences, Boston, MA) and carried out at
25 °C as most of the previous biophysical studies on calmodulin
have been done at this temperature. Binding assays were conducted
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(Model 3686; Corning, Acton, MA) and handled by a Biomek 2000
robot. The FP-titrations were planned by adding to each well, succes-
sively, 15 μL of a mixture of SynCaM (2 μM) and the 16B05 ortho
isomer probe (0.2 μM) in the assay buffer (50 mM Hepes, 150 mM KCl,
CaCl2 10 μM pH 7.5) and 15 μL of CaM interactors, in the same buffer
with ﬁnal concentrations ranging from 0.5 to 500 μM in a ﬁnal volume
of 30 μL. In experiments performedwith 17F07 (probe S3), CaM concen-
tration were in the 5 µM range. The ﬁnal DMSO concentration in the
assay buffer was less than 1%. The plate was shaken and incubated for
5 min at room temperature. The polarization degrees (P)weremeasured
with an excitation wavelength set at 530 nm (bandwidth 7 nm) and an
emission wavelength set at 610 nm (bandwidth 10 nm). For each plate,
P were measured versus control wells containing 16B05 or 17F07 ortho
isomer bound to SynCaM and the ortho isomer probe alone (unbound
probe). Probe displacement by different concentrations of CaM
interactors was monitored by steady-state ﬂuorescence polarization.
Equilibrium parameters were determined by non-linear curve ﬁtting
using the general framework described by Roehrl et al. [17].
2.8. Isothermal microcalorimetry titration of CaMwith selected interactors
The thermodynamic parameters of CaM inhibitors binding to SynCaM
weremeasured using a ITC200 instrument (MicroCal, Northampton,MA,
USA) as described previously [18]. Experimentswere carried out at 25 °C
in 50 mM Hepes buffer in the presence of 2 mM CaCl2 and 2% DMSO,
pH 7.5. 2-μL aliquots of CaM inhibitors were injected into a 0.2 mL
cell containing the SynCaM solution to achieve a complete binding
isotherm. Concentration of SynCaM in the cell was 15 μM and
concentration of CaM inhibitors in the syringe ranged from 0.15 to
0.75 mM. The heat of dilution was measured by injecting the ligand
into the buffer solution or by additional injections of ligand after
saturation; the values obtained were subtracted from the heat of
reaction to obtain the effective heat of binding. ITC baseline was always
stable without any signs of precipitation. The resulting titration curves
were ﬁtted by MicroCal Origin software using the model of two sets of
independent binding sites. Among the different models provided by
MicroCal origin software, the model of two sets of independent sites
gave the best ﬁt. Afﬁnity constants (Ka), binding stoichiometry (N) and
enthalpy (ΔH) were determined by a non-linear regression ﬁtting pro-
cedure. ITCmeasurements for each CaM inhibitor have been repeated at
least three times and yielded similar thermodynamic parameters.
2.9. FP-competitive binding assay between CaM-interactors and synthetic
peptides
The interaction between CaM and TAMRA-tagged ﬂuorescent pep-
tides in the presence of interactors was studied by FP-measurements
using a Victor3 (Perkin-Elmer Life and Analytical Sciences, Boston,
MA) at 25 °C. For this purpose, peptides at 0.1 μM were titrated with
1 μM of CaM and various concentrations of interactors (1–2–4–8–16–
32–64–125–250–500–1000 μM). Assays were conducted in a 30 mM
MOPS buffer, 100 mM KCl and 100 μM CaCl2, pH 7.2.
Solutions composed of 0.2 μM of peptides and 2 μM of CaM were
distributed robotically (BiomeK 2000, Beckman Coulter) in 96 well
microplates (Corning Costar 3686, Acton, MA). Stock solutions of
interactors (50 mM in DMSO) were prepared and were serially diluted
to obtain concentrations ranging from 0.02 to 2000 μM. The binding as-
says were performed by adding robotically (BiomeK FX, Beckman Coul-
ter) 7.5 μL of interactor to each well containing 7.5 μL of ﬂuorescent
peptide and CaM mix. The ﬁnal interactor concentration thus ranged
from 1 μM to 1000 μM for a peptide concentration of 0.1 μM and a
CaM concentration of 1 μM. The plate was mixed and incubated for
5 min at room temperature. The polarization degrees (P) were mea-
sured with an excitation wavelength set at 544 nm (bandwidth
15 nm) and an emission wavelength set at 600 nm (bandwidth10 nm). For each plate, FP-measurements were performedwith control
wells containing the unbound ﬂuorescent peptide. During titration, the
equilibrium ratio of free over total ﬂuorescent probe concentration was
monitored by ﬂuorescence polarization. The halfmaximal effective con-
centration (IC50) of interactors able to inhibit peptide binding to CaM
was calculated by ﬁtting the sigmoid dose-dependent with the Hill
equation (the Hill equation is a phenomenological equation that was
ﬁtting reasonably well our experimental data points):
P ¼
Pmax þ Pmin 

1
IC50  x
 nh
1þ 1IC50  x
 nh
where x is the concentration of CaM interactor, IC50 stands for the
concentration of interactor that gives 50% binding inhibition and nh is
the Hill coefﬁcient that describes the slope of the curve when the
concentration of antagonist is equal to the IC50. Pmax is the maximal
polarization under the experimental conditions used. As the concentra-
tion of CaM is 1 μM and the concentration of labeled peptide is 0.1 μM,
the Pmax value is an indication of the afﬁnity between CaM and a given
peptide. Pmax may vary from one experiment to the other due to small
changes in CaM concentration. Pmin represents the minimum polariza-
tion reached in the experiment. In the present experiments, Pmin is
equal to the polarization of the free tagged peptide, indicating that the
different CaM interactors are able to dissociate the complexes formed
between CaM and its binding domains.3. Results and discussion
3.1. Identiﬁcation of CaM interactors by screening the Strasbourg Academic
Library and selection of compounds for further use in CaM/CaM peptide
interaction studies
A previous screen of the Prestwick chemical library using ﬂuores-
cence polarization disclosed 11 chemical molecules interacting with
CaM, amongwhich is triﬂuoperazine, oneof thewell knownCaMantag-
onists [14]. Using the same approach, the Strasbourg Academic Library
consisting of 5300 compounds, was screened at 10 μM ﬁnal concentra-
tion with 0.1 μM ﬂuorescent probe (16B05 (probe S1) or 17F07 (probe
S3)) bound to 2 μM SynCaM in the presence of 10 μM Ca2+ in a ﬁnal
volume of 30 μL per well. The experimental setup is based on competi-
tive ﬂuorescence polarization that monitors the change in ﬂuorescence
polarization of a given probe (S1 or S3) upon binding of a compound of
the chemical library to SynCaM. The free ﬂuorescent probes show low
polarization values, whereas the bound probes exhibit high values.
The performance of the assay was measured by analyzing statistical
quality parameters, such as the Z′ factor [19]. The Z′ factor quantiﬁes the
difference that separates the signals corresponding to the polarization
degree of the bound ligand and the free ligand in the FP-screening
assay and accounts for the observed variability. A Z′ value of 0.85 was
calculated from our data. Typically, an assay in which 0.5≤Z′≤1 is con-
sidered excellent.
Screening the Strasbourg Academic Library revealed 39 molecules
able to interact with CaM. Among those 39 positive hits, six were
selected as they were distributed into two homogenous chemical
families, each composed of three molecules. Such molecules are ade-
quate tools for deeper analysis of the CaM interaction properties. Addi-
tionally, triﬂuoroperazine (TFP), an extensively studied molecule that
has been largely employed as CaM inhibitor, was used as control
(Fig. 1).
The three N-(2-naphthylmethyl) ethane-1, 2-diamine derivatives
(Fig. 1 upper panel) compose ourﬁrst family ofmolecules. Themembers
differ by the presence on the benzene ring of either an \OH or a \Cl
group.
LPS02-10-L-D02 LPS02-10-L-C08 LPS02-20-L-B05
LPS01-18-L-B10 LPS01-18-L-D04 LPS01-18-L-C06
TFP
N
NH2
N
NH2
OH
N
NH2
Cl
N N
N
H
N
N N
N
H
N N N
N
H
N
N
S
N
N
CH3
F
F
F
Fig. 1. Chemical structures of the CaM interactors selected after screening the Strasbourg Academic Library and hit validation. The upper panel presents the structures of the
molecules forming family 1, the middle panel presents those forming family 2 molecules and the lower panel corresponds to the structure of triﬂuoroperazine.
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constitute family 2. They differ by the length of the alkyl chain with 5,
6 or 7 carbons.
3.2. Interaction characteristics of the CaM interactors evaluated using
ﬂuorescence polarization titration experiments
To characterize the mode of binding of the CaM antagonists, we
used the ﬂuorescent polarization assay previously described [14].
The two ﬂuorescent probes S1 and S3 that bind to CaM with high
afﬁnity in a calcium dependent manner were competed with the
aforementioned selected CaM antagonists (Fig. 1). The level of
probe binding to CaM was monitored by ﬂuorescence polarization.
In our experimental conditions, the S1 and S3 probes bind to one
site on CaM with dissociation constants of 0.16 μM and 0.89 μM, re-
spectively. Under the experimental conditions used, CaM and probe
concentrations were kept constant (from 0.5 to 2 μM in the different
experiments for CaM and 0.1 μM for the probe), and the calmodulin
interactor concentrations ranged from 0.5 to 500 μM. Monitoring
the ﬂuorescence polarization changes of the probe during titration
of the CaM-probe complex with the different CaM interactors gives
information on whether the antagonists bind to the same site as the
ﬂuorescent probe or to one or several additional different sites
(Fig. 2).
As illustrated in Fig. 2, two possibilities were considered for the
interaction of CaM with the chemical compounds:
1) A simple competition with the S1 or S3 probes. Such competition
is described by the equation presented in Dagher et al. [14]. In
this case, as the dissociation constant for each probe is knownfrom previous experiments (namely 0.16 μM for probe S1 and
0.89 μM for probe S3), the dose response curves established
from titration data give access to the dissociation constant Ki
between CaM and each CaM interactor. We assume that the two
probes bind to the same or neighboring domains as the calcium
dependency of the probe binding is similar (data not shown).
2) An allosteric mechanism where the antagonist binds to one or
several sites that differ from the probe site. Even in this case, the
apparent titration by a CaM antagonist appears as a competition
with the probe.
As presented in Fig. 3, the displacement of probes S1 and S3 from
CaM induced by the different CaM antagonists is reasonably ﬁtted by
a competitive model between the probes and the different antagonists.
This competitive model was chosen as it allowed ﬁtting the raw data
with the minimum number of parameters. However, those results do
not exclude the possibility of other binding sites for the antagonists.
Indeed, either the molecule competes directly with the probe or the
binding site of the molecule is negatively coupled to the probe binding
site. The parameters used to ﬁt the experimental data, as well as the
residual mean square (RMS) illustrating the quality of the ﬁt, are sum-
marized in Table 1.
In the ﬁrst group, the molecule with the chloride group on the
benzene ring (B05) exhibits an afﬁnity almost 5 fold higher than the
one with the benzene (D02) ring and 10 fold higher than the molecule
with a phenol (C08). This result is reminiscent of the properties of the
couple of CaM antagonists designed by Hidaka [20], namely W7 and
W5. In our hand, W7 has an afﬁnity 10 times lower than the molecule
B05 (data not shown). In the second group, the molecules with the
alkyl chain of length 6 or 7 present almost the same afﬁnity whereas
S1
S3
CaM
H
N
O
N
H
O
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NHH2N
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H
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-
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S1 Competition
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Fig. 2. The two possible schemes considered for the interaction of CaM with its antagonists. The probes S1 or S3 bound to CaM can be displaced by a CaM interactor (arrowhead)
either by direct competition (blue arrowhead) or by an allosteric mechanism (purple arrowhead).
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times lower.
By comparison, triﬂuoroperazine has a Ki of 1 μM (data not
shown) in agreement with values reported in the literature.
So far, our study allowed us to characterize two groups of three
molecules, each group belonging to a homogeneous chemical class.
Those molecules exhibit different afﬁnities for CaM and can thus be
used as pharmacological tools allowing to differentiate cellular effects
due to CaM or to off target proteins. Indeed, we may expect that when
used to inhibit a cellular event involving CaM, for each family, the
molecule with the highest afﬁnity would be more potent than the
molecule with the lowest afﬁnity. In other terms, for the family 1,
the molecule B05 should show more efﬁcacy than the molecule C08.
Following the same rationale for the family 2, the molecule C06
must be more potent that the molecule B10.
Moreover, following this simple rationale, if the molecules in the
two chemical families, behave similarly, we may expect that B05
(family 1) would be more potent than the molecule C06 (family 2).
More generally, we may expect that the potency of each molecule
to inhibit a cellular event involving CaMwill exhibit the same ranking
than the binding constants of that molecule for CaM.3.3. Thermodynamic approach to characterize the binding mechanism of
CaM-interactors
In order to get more insight into the molecular mechanism of
binding of the selected molecules to CaM, wemonitored their interac-
tion by microcalorimetry in a medium without KCl and containing 2%
DMSO. The experimental conditions were designed to get reproducible
data with a good signal to noise ratio.
The thermodynamic parameters for each molecule obtained from
the titration curves presented in Fig. 4 are given in Table 2.
The calorimetric study qualitatively conﬁrms the results obtained by
ﬂuorescence polarization in terms of ranking of the binding afﬁnities of
the different molecules for CaM. Under the experimental conditions
used, the molecules of family 1 exhibit one high afﬁnity binding site in
the nM range and two low afﬁnity sites in the μM range. Similarly, the
molecules of family 2 exhibit one high afﬁnity binding site in the
10 nM range and 3 sites in the μM range. The afﬁnity increases as the
alkyl chain elongates. In all cases, the binding is entropically and
enthalpically driven. For the different molecules, the relative ranking
of the afﬁnity constants is similar when considering the binding con-
stants of the high afﬁnity sites obtained by calorimetric titration or the
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Fig. 3. Displacement of probes S1 and S3 by each of the selected CaM interactors. The six compounds presented in Table 1 and belonging to either family 1 (three compounds) or
family 2 (three compounds) were tested for their potential to inhibit the binding to CaM of probe S1 (left panels) and probe S3 (right panels). Fluorescence polarization of the
ﬂuorescent probes S1 and S3 is followed as a function of CaM antagonists' concentration. Upper panel: family 1 CaM antagonists (■-•-■ stands for B05, ▲–▲for D02 and ♦__♦
for C08). Lower panel: family 2 CaM antagonists (■-•-■ stands for B10, ▲–▲ for D04 and ♦__♦ for C06). The data were ﬁtted with a model of direct competition between the
ﬂuorescent probes S1 or S3 and the different CaM antagonists as described in [17]. CaM's concentrations range from 0.9 μM to 1.4 μM when used with probe S1 (0.1 μM) and
from 2 to 4 μMwhen used with probe S3 (0.1 μM). Kd values for probe S1 and probe S3 binding to CaM are 0.16 μM and 0.89 μM, respectively. Ordinate correspond to polarization
degrees P x 1000.
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values arising from FP studies are higher than the dissociation constants
(Kd) obtained by calorimetry. The fact that the FP titration conditions
differ from those used in the calorimetric studies by the presence, inTable 1
Parameters used to ﬁt the data of Fig. 3 and residual mean square values for each
ﬁt. Methods used for data ﬁtting are fully described in [17]. Pmax is experimentally
determined to be 420 (mP). Ki is the dissociation constant expressed in μM.
Molecules Ki Pmin RMS
Family 1
LPS 02-10-L-D02_S1 2.02 159.12 62.43
LPS 02-10-L-D02_S3 2.52 161.33 41.76
LPS 02-10-L-C08_S1 4.85 157.80 62.63
LPS 02-10-L-C08_S3 4.07 167.47 100.84
LPS 02-20-L-B05_S1 0.48 166.79 65.81
LPS 02-20-L-B05_S3 0.46 165.89 50.12
Family 2
LPS 01-18-L-B10_S1 6.75 170.39 21.79
LPS 01-18-L-B10_S3 5.40 179.37 34.90
LPS 01-18-L-D04_S1 1.53 163.79 42.70
LPS 01-18-L-D04_S3 1.79 168.77 43.66
LPS 01-18-L-C06_S1 1.02 157.81 76.62
LPS 01-18-L-C06_S3 1.56 164.87 61.62the former, of 150 mM KCl points to a decrease of the overall afﬁnity
of the antagonists for CaM induced by the ionic strength.
3.4. Inhibition of the interaction between CaM and eight different CaM
binding domains
In order to characterize the inhibitory potency of each of the six
CaM antagonists, we selected 8 different CaM/Ca2+ binding domains
and studied their interaction with CaM/Ca2+ in the absence and
presence of the different antagonists. Each CaM binding domain is
tagged with a ﬂuorescent probe (TAMRA) as previously described
[15] allowing the study of its interactionwith CaM by FP. The sequences
of the eight CaM binding domains (CBD) are given in Table 3. They
correspond to:
• The CBDs of the plasma membrane calcium pump (PMCA) and the
IQ domain of the L-type voltage dependent calcium channel (CaV),
• The CBDs of three CaM dependent kinases, namely the death asso-
ciated protein kinase 2 (DAPK2), the smooth muscle myosin light
chain kinase (smMLCK) and the skeletal myosin light chain kinase
(skMLCK),
• Finally, the CBDs of three other CaM dependent enzymes, namely the
CBD of the nitric oxide synthase of endothelial cell (eNOS), the CBD of
the phosphatase PP3CA (calcineurin) and the CBD of the cAMP phos-
phodiesterase (PDE1A).
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ﬂuorescent probe is the same, the polarization must be the same if the
peptide is in the monomeric form. The data presented in Table 3 indi-
cate that all the peptides are in a monomeric form except the IQ
domain of the voltage dependent calcium channel (CaV), the CaM
binding domain of the plasma membrane calcium pump (PMCA) and
DAPK2, which appears to associate in solution probably as dimers. The
sequence of the CBD of DAPK2 is similar to the CBD sequences of the
two other kinases (smMLCK and skMLCK) that are in a monomeric
form. We may notice that DAPK2 is the only sequence to contain a cys-
teine residue and to have a leucine instead of a lysine in position 6.
The interaction of a ﬂuorescently tagged CBD with CaM was mon-
itored by recording its polarization as the CaM antagonists are added
to the solution. The polarization is high in the absence of interactors.
Addition of a given CaM antagonist lowers the polarization. CBD
displacement is ﬁtted using the Hill equation as presented in the Ex-
perimental section (Section 2.9).3.4.1. Inhibition of the binding of the plasma membrane calcium pump
and the L-type calcium channel CBDs to CaM
CaM in a calcium dependent manner activates the plasma calcium
pump and in a similar manner facilitates or inactivates calcium entry
through modulation of calcium channels. Therefore, CaM antagonists
may modulate calcium homeostasis when applied to a given cell line
[21]. In order to get more insight into this phenomenon, we focus in
the present section on two CBDs involved in calcium signaling and
modulation of calcium homeostasis. The displacement of the different
CBDs from CaM as a function of CaM antagonist's concentration is
presented in Fig. 5. The insets represent the relationship betweenTable 2
Thermodynamic parameters of the six CaM antagonists. N corresponds to the number of bindin
the dissociation constant (=1/Ka), ΔH is the change in enthalpy,ΔS is the change in entropy, a
molecule obtained from the ﬂuorescence polarization (FP) experiments presented in Fig. 3.
Molecules N Ka, M−1 Kd, nM
LPS 02-10-L-D02 0.4 3.20E+07 31.3
2.3 7.40E+05 1351.4
LPS 02-10-L-C08 0.6 2.90E+07 34.5
2.1 1.30E+06 769.2
LPS 02-20-L-B05 0.8 2.00E+08 5
2.2 7.00E+06 142.9
LPS 01-18-L-B10 0.9 3.90E+07 25.6
3.1 5.80E+05 1724.1
LPS 01-18-L-D04 0.9 6.30E+07 15.9
3 7.10E+05 1408.5
LPS 01-18-L-C06 0.8 1.30E+08 7.7
3.3 1.40E+06 714.3the IC50 for a given CBD versus the Ki for each CaM antagonist. Two
points can be noticed:
• In a given family, there is a reasonable exponential ﬁt of the data,
• The two families appear to be uncorrelated. This suggests that the
molecules of a given family bind to the same site with different
afﬁnities and the molecules of the two families bind to different
sites on CaM.
Although the two families of molecules present similar afﬁnities, the
molecules of family 2 have a better inhibition potential for the calcium
pump than the molecules of family 1 (the curve with the red squares
on the right is compared to the curve with blue diamond). The opposite
is seen with the calcium channel CBD. This suggests that the site where
the CaM antagonist of a given family binds varies with the CaM/CBD
complex. The present results suggest that it is preferable to use the
molecules of family 2 to inhibit the plasma membrane calcium pump
and the molecules of family 1 to inhibit the L-type calcium channels.
3.4.2. Inhibition of the binding to CaM of three CaM dependent protein
kinase CBDs
CaM modulates the activity of a group of serine-kinases named
CaM dependent kinases. We have previously analyzed the calcium
dependency of the CBD of death associated protein kinase 1 (DAPK1)
[15]. In this section of our study, we focus on three other CaM-
dependent kinases, namely DAPK2 as well as the myosin light chain
kinases from skeletal and smooth muscle.
The results are presented in Fig. 6 using the same format as in Fig. 5.
For the two families of molecules and TFP, the inhibition potential is
similar with IC50 in the 100 μM range. The molecules of each familyg sites, Ka to the association constants between CaM and each of the six antagonists, Kd to
nd T is the temperature (°K). Ki is themean dissociation constants between CaM and each
ΔH, kCal M−1 TΔS, kCal M−1 Ki μM
−5.3 4.9 2.27
−1 7
−9.5 0.7 4.46
−0.5 7.8
−5.4 5.9 0.47
−1.4 8
−4.8 5.6 6.07
−0.7 7.2
−4.7 5.9 1.66
−1.5 6.5
−3.9 7.1 1.29
−1.8 6.6
Table 3
List and parameters of the CaM binding domains. Most of the peptides have been co-crystallized with CaM except the CBD of cAMP phosphodiesterase (PDE1A). Mw stands for the
molecular weight of the peptide. Polarization corresponds to the value of the polarization degree (P x 1000) of the TAMRA-labeled peptide. In the column PDB, the name of the
co-crystal in the protein data bank is reported [22–27].
Description Sequence of the peptide Position in the sequence Mw Name Polarization PDB
Ca2+ pump N-terminal domain TAMRA-LRRGQILWFRGLNRIQTQIK-NH2 1123–1142 2907.5 PMCA 210 2KNE
Cardiac Ca(v)1.2; alpha-1C TAMRA-KFYATFLIQEYFRKFKKRKEQ-NH2 1665–1685 3209.8 CaV 206 2F3Y
Death-associated protein kinase 2 TAMRA-RRRWKLSFSIVSLCNHLTR-NH2 312–330 2783.3 DAPK2 224 1WRZ
sk-Myosin light chain kinase TAMRA-KRRWKKNFIAVSAANRFKKI-NH2 566–585 2872.5 smMLCK 160 2BBN
sm-Myosin light chain kinase TAMRA-RRKWQKTGNAVRAIGRLSSM-NH2 1742–1761 2726.2 skMLCK 164 2K0F
Nitric-oxide synthase, endothelial TAMRA-RKKTFKEVANAVKISASLMG-NH2 492–511 2589.1 eNOS 155 1NIW
Calcineurin TAMRA-AAARKEVIRNKIRAIGKMARVFSVL-NH2 389–413 3208.9 Calcineurin 164 2R28
cAMP Phosphodiesterase TAMRA-KPRFRSIVHVVQAGIFVERM-NH2 115–134 2780.3 PDE1A 165 ND
1727E. Audran et al. / Biochimica et Biophysica Acta 1833 (2013) 1720–1731with the highest afﬁnity inhibit the different CaM dependent kinases
similarly. In this case, the two binding sites of each family are equally
modiﬁed in the CBD–CaM complexes for the three CaM dependent ki-
nases (see inset Fig. 6).
3.4.3. Inhibition of the binding of NO synthase, calcineurin and phospho-
diesterase 1A CBDs to CaM
This section presents the interaction between CaM and the CBDs
of nitric oxide synthase, the phosphatase calcineurin and cAMP phos-
phodiesterase 1A. Results are given in Fig. 7.
For NO synthase and calcineurin, the behavior of the two families
of molecules is similar to the one observed for the CaM dependent
kinases whereas for the phosphodiesterase, a slightly better inhibi-
tion is obtained with the molecules of the family 1.190
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six CaM antagonists belonging to two chemical families (see Fig. 1). Ordinate corresponds
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has been done at least twice. Error bars are not represented in the ﬁgures for sake of clarity buTable 4 gathers the IC50s and the Hill coefﬁcients used to ﬁt the ex-
perimental data shown in Figs. 5 to 7. In each family of molecules and
for all peptides, we observe a constant trend with IC50C08~IC50D02>
IC50B05 for the naphthalene derivatives and IC50B10>IC50D04>IC50C06
for the aminopyridazine derivatives. However, this trend does not hold
when considering the whole set of molecules with the whole set of
CBDs. This suggests that we have at least two binding sites on CaM,
one site for each chemical family. The family 1 molecules binding site
(respectively the family 2 binding site) must be allosterically coupled
to the binding sites of each CBD but in a different manner for each
CBDpeptide. Indeed, if it was not the case, for all CBDs, the two chemical
families of molecules would behave the same way, meaning one set of
molecules would always be a better inhibitor than the other set or the
two sets would have the same potency for all CBDs.190
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Fig. 6. Inhibition of the interaction between CaM and calcium binding domains (CBDs) by CaM antagonists. The interaction between CaM and the ﬂuorescently labeled CBDs derived from the death associated protein kinase 2, the myosin
light chain kinases from smooth muscle and the skeletal muscle by six CaM antagonists (Table 1). Fluorescence polarization of the ﬂuorescent CBDs was followed upon titration of CaM by CaM antagonists belonging to chemical family 1
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Table 4
IC50 values of each CaM antagonist for each CaM binding peptide obtained from experiments described in Figs. 5 to 7. IC50 is expressed in μM. The Hill coefﬁcient of each curve is
indicated between parentheses.
Molecules PMCA Cav DAPK2 skMLCK smMLCK eNOS Calcineurin PDE1A
D02 633(2) 596(1.3) 940(2.3) 1908(.8) 596(1.3) 142(2.2) 714(.5) 102(1.2)
C08 809(2) 620(1.6) 1202(2.3) 2024(.8) 621(1.6) 206(2.2) 1562(.5) 279(1.7)
B05 183(2) 118(2) 204(3.4) 198(1.3) 118(2) 38(2.2) 148(.7) 33(1.7)
B10 126(1.6) 2981(1.8) 1082(1.1) 2396(.9) 1975(1.1) 466(2) 685(1.3) 302(1.0)
D04 33(1.6) 1045(1.8) 726(1) 919(.9) 347(1.6) 93(2.2) 189(1.2) 125(1.8)
C06 21(2) 347(1.8) 166(.9) 221(1.2) 120(1.9) 35(1.7) 119(1.1) 64(1.9)
TFP 105(1.9) 453(2) 543(.8) 506(.9) 264(1.9) 63(2.6) 236(1.2) 50(1.2)
1730 E. Audran et al. / Biochimica et Biophysica Acta 1833 (2013) 1720–1731Altogether, the two families of CaM antagonists can be used to get
a typology of the CaM-Ca2+/CBD complexes. Three types of complex
may be deﬁned:
• The ones that are slightly better inhibited by the compounds of family
1 rather than those of family 2. The L-type calcium channel and PDE1A
CBDs belong to this group. For these two CBDs, themolecule B05 has a
better afﬁnity than themolecule C06, although the afﬁnity is weak for
the L-type calcium channel CBD.
• The complexes where the two families of molecules exhibit a similar
inhibition potential. This group is composed of the CBDs of the three
CaM dependent kinases (DAPK2, MLCK from skeletal muscle and
smooth muscle), of NO synthase and of calcineurin,
• The complexes where the molecules of family 2 inhibit the CaM/CBD
complex better than themolecules of family 1. The CBDs of the plasma
membrane calcium pump and cAMP phosphodiesterase 1A belong to
this group.
4. Conclusion
The present study presents a general frame to detect CaM
interactors in small molecule libraries and to characterize them. We
have also set up a new strategy to analyze their ability to inhibit the
interaction between CaM and different CaM binding proteins. Using a
library composed of 5300 small molecules, two new chemical families
of CaM antagonists were disclosed. In each family, three molecules
exhibiting different afﬁnities for CaM were characterized. These mole-
cules pave the way for a more precise pharmacological study of CaM
and its interaction with partners.
Moreover, to get more insight into the six selected CaM interactors,
we have analyzed their potential to inhibit the interaction between CaM
and a diverse set of CBDs. The inhibition potentials of the newly identi-
ﬁed molecules were compared to those of the classical CaM antagonist,
namely triﬂuoperazine (TFP).
This report shows the potential of small molecules to discriminate
between different CaM/CBD complexes and thereby rejuvenates the
pharmacology of CaM.
New screening tests using the ﬂuorescently-tagged CBDs to detect
molecules that inhibit a speciﬁc CaM complex may be set up. To be
able to ﬁnd molecules speciﬁc of a given CBD, it will be necessary to
differentially screen small molecule libraries. Taking into account
the number of proteins that interact with CaM and therefore, the
number of CBDs, automation and miniaturization of the assay will be
necessary. However, the effort is worth as CaM appears to be a hub
protein in numerous important pathways within a cell and therefore,
appears to be a strategic target to pinpoint in cancer and inﬂammatory
diseases. The strategy presented in this report may be used to analyze
the interaction between two proteins in a systematic way. Such a
quest is becoming the grail of pharmaceutical companies.
Acknowledgements
This work was supported by CNRS and University of Strasbourg.
E. Audran has been co-ﬁnanced by Transgene and Region Alsace. Thiswork was supported by the Molecular and Cellular Biology Program of
the Russian Academy of Sciences.
References
[1] M. Ali, F. Ponchel, K.E. Wilson, M.J. Francis, X. Wu, A. Verhoef, A.W. Boylston, D.J.
Veale, P. Emery, A.F. Markham, J.R. Lamb, J.D. Isaacs, Rheumatoid arthritis synovial
T cells regulate transcription of several genes associated with antigen-induced
anergy, J. Clin. Invest. 107 (2001) 519–528.
[2] J. Martinez, I. Moeller, H. Erdjument-Bromage, P. Tempst, B. Lauring, Parkinson's
disease-associated alpha-synuclein is a calmodulin substrate, J. Biol. Chem. 278
(2003) 17379–17387.
[3] D.H. O'Day,M.A.Myre, Calmodulin-binding domains inAlzheimer's disease proteins:
extending the calcium hypothesis, Biochem. Biophys. Res. Commun. 320 (2004)
1051–1054.
[4] J. Haiech, J.C. Cavadore, C. Le Peuch, Calcium signal and calcium antagonists,
J. Pharmacol 16 (1985) 215–225.
[5] M.H. Olofsson, A.M. Havelka, S. Brnjic, M.C. Shoshan, S. Linder, Charting calcium-
regulated apoptosis pathways using chemical biology: role of calmodulin kinase
II, BMC Chem. Biol. 8 (2008) 2.
[6] M. Vandonselaar, R.A. Hickie, J.W. Quail, L.T. Delbaere, Triﬂuoperazine-induced
conformational change in Ca(2+)-calmodulin, Nat. Struct. Biol. 1 (1994) 795–801.
[7] M. Osawa, M.B. Swindells, J. Tanikawa, T. Tanaka, T. Mase, T. Furuya, M. Ikura,
Solution structure of calmodulin-W-7 complex: the basis of diversity in molecular
recognition, J. Mol. Biol. 276 (1998) 165–176.
[8] V. Harmat, Z. Bocskei, G. Naray-Szabo, I. Bata, A.S. Csutor, I. Hermecz, P. Aranyi, B.
Szabo, K. Liliom, B.G. Vertessy, J. Ovadi, A new potent calmodulin antagonist with
arylalkylamine structure: crystallographic, spectroscopic and functional studies,
J. Mol. Biol. 297 (2000) 747–755.
[9] J.S. Shim, J. Lee, K.N. Kim, H.J. Kwon, Development of a new Ca2+/calmodulin
antagonist and its anti-proliferative activity against colorectal cancer cells,
Biochem. Biophys. Res. Commun. 359 (2007) 747–751.
[10] J.S. Shim, J. Lee, H.J. Park, S.J. Park, H.J. Kwon, A new curcumin derivative, HBC,
interferes with the cell cycle progression of colon cancer cells via antagonization
of the Ca2+/calmodulin function, Chem. Biol. 11 (2004) 1455–1463.
[11] J. Haiech, C. Pigault, R. Dagher, P. Villa, M.C. Kilhoffer, Calcium binding proteins as
therapeutic targets, Med. Sci. (Paris) 22 (2006) 1020–1022.
[12] H.M. Schuller, M. Orloff, G.K. Reznik, Antiproliferative effects of the Ca2+/
calmodulin antagonist B859-35 and the Ca(2+)-channel blocker verapamil on
human lung cancer cell lines, Carcinogenesis 12 (1991) 2301–2303.
[13] J.S. Strobl, V.A. Peterson, Tamoxifen-resistant human breast cancer cell growth:
inhibition by thioridazine, pimozide and the calmodulin antagonist, W-13,
J. Pharmacol. Exp. Ther. 263 (1992) 186–193.
[14] R. Dagher, C. Pigault, D. Bonnet, D. Boeglin, C. Pourbaix, M.C. Kilhoffer, P. Villa, C.G.
Wermuth, M. Hibert, J. Haiech, Use of a ﬂuorescent polarization based high
throughput assay to identify new calmodulin ligands, Biochim. Biophys. Acta
1763 (2006) 1250–1255.
[15] R. Dagher, S. Peng, S. Gioria, M. Feve, M. Zeniou, M. Zimmermann, C. Pigault, J.
Haiech, M.C. Kilhoffer, A general strategy to characterize calmodulin–calcium
complexes involved in CaM-target recognition: DAPK and EGFR calmodulin binding
domains interact with different calmodulin–calcium complexes, Biochim. Biophys.
Acta 1813 (2011) 1059–1067.
[16] D.M. Roberts, R. Crea, M. Malecha, G. Alvarado-Urbina, R.H. Chiarello, D.M.
Watterson, Chemical synthesis and expression of a calmodulin gene designed
for site-speciﬁc mutagenesis, Biochemistry 24 (1985) 5090–5098.
[17] M.H. Roehrl, J.Y. Wang, G. Wagner, A general framework for development and
data analysis of competitive high-throughput screens for small-molecule inhibitors
of protein–protein interactions by ﬂuorescence polarization, Biochemistry 43
(2004) 16056–16066.
[18] A.A. Makarov, P.O. Tsvetkov, C. Villard, D. Esquieu, B. Pourroy, J. Fahy, D. Braguer,
V. Peyrot, D. Laﬁtte, Vinﬂunine, a novel microtubule inhibitor, suppresses
calmodulin interactionwith the microtubule-associated protein STOP, Biochemistry
46 (2007) 14899–14906.
[19] P.W. Iversen, B.J. Eastwood, G.S. Sittampalam, K.L. Cox, A comparison of assay
performance measures in screening assays: signal window, Z′ factor, and assay
variability ratio, J. Biomol. Screen. 11 (2006) 247–252.
[20] H. Hidaka, M. Asano, S. Iwadare, I. Matsumoto, T. Totsuka, N. Aoki, A novel vascular
relaxing agent, N-(6-aminohexyl)-5-chloro-1-naphthalensulfonamide which affects
vascular smooth muscle actomyosin, J. Pharmacol. Exp. Ther. 207 (1978) 8–15.
1731E. Audran et al. / Biochimica et Biophysica Acta 1833 (2013) 1720–1731[21] R. Dagher, C. Briere, M. Feve, M. Zeniou, C. Pigault, C. Mazars, H. Chneiweiss, R.
Ranjeva, M.C. Kilhoffer, J. Haiech, Calcium ﬁngerprints induced by calmodulin
interactors in eukaryotic cells, Biochim. Biophys. Acta 1793 (2009) 1068–1077.
[22] N. Juranic, E. Atanasova, A.G. Filoteo, S. Macura, F.G. Prendergast, J.T. Penniston,
E.E. Strehler, Calmodulin wraps around its binding domain in the plasma mem-
brane Ca2+ pump anchored by a novel 18–1 motif, J. Biol. Chem. 285 (2010)
4015–4024.
[23] J.L. Fallon, D.B. Halling, S.L. Hamilton, F.A. Quiocho, Structure of calmodulin bound
to the hydrophobic IQ domain of the cardiac Ca(v)1.2 calcium channel, Structure
13 (2005) 1881–1886.[24] M. Ikura, G.M. Clore, A.M. Gronenborn, G. Zhu, C.B. Klee, A. Bax, Solution structure
of a calmodulin-target peptide complex by multidimensional NMR, Science 256
(1992) 632–638.
[25] J. Gsponer, J. Christodoulou, A. Cavalli, J.M. Bui, B. Richter, C.M. Dobson, M.
Vendruscolo, A coupled equilibrium shift mechanism in calmodulin-mediated
signal transduction, Structure 16 (2008) 736–746.
[26] M. Aoyagi, A.S. Arvai, J.A. Tainer, E.D. Getzoff, Structural basis for endothelial nitric
oxide synthase binding to calmodulin, EMBO J. 22 (2003) 766–775.
[27] Q. Ye, H. Wang, J. Zheng, Q. Wei, Z. Jia, The complex structure of calmodulin
bound to a calcineurin peptide, Proteins 73 (2008) 19–27.
